AVA. I. Vlasenko

A. I. Vlasenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


A. I. Vlasenko has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Phenotypic heterogeneity of Charcot–Marie–Tooth type 2A disease associated with the c.1091G>C missense mutation (p.Arg364Pro) in the MFN2 gene

    by T.M. Alekseeva, A.I. Vlasenko, V.S. Demeshenok, T.A. Pavlova, A.YU. Smirnova, Yu.V. Fomicheva, A.A. Kostareva

    Charcot–Marie–Tooth disease belongs to the group of genetically and phenotypically heterogeneous sensory-motor polyneuropathies. Charcot–Marie–Tooth disease type 2A (CMT2A) is the most common axonal form of the disease caused by mutations in the mitofusin-2 gene (MFN2). More than 100 missense mutations in this gene have been registered to date. Many studies have demonstrated the variability of clinical presentation depending on the specific localization of the substitution. The presented clinical case shows the peculiarities of the phenotype of a patient with CMT2A disease associated with the c.1091G>C (p.Arg364Pro) missense mutation in the MFN2 gene.

  • Challenges of differential diagnosis in the verification of Behçet’s disease with neurological manifestations

    by A.I. Vlasenko, M.P. Topuzova, V.A. Malko, G.N. Bisaga, T.A. Pavlova, A.P. Abramova, A.O. Chistyakova, T.M. Alekseeva

    Behçet’s disease (BD) is an autoimmune vasculitis of unclear etiology characterized by a wide range of systemic manifestations. The nervous system is involved in approximately 10% of patients with BD (neuro-Behçet). Diagnosis of neuro-Behçet is challenging, especially in the case of BD onset with neurological manifestations, and is based on a combination of clinical, laboratory, and neuroimaging data. To verify the diagnosis of neuro-Behçet, a wide range of conditions with similar manifestations must be ruled out: multiple sclerosis, neuromyelitis optica spectrum disorder, neurosarcoidosis, and many rare autoimmune diseases (e.g., Cogan syndrome, Susac syndrome, Vogt-Koyanagi-Harada syndrome). This article presents a brief literature review highlighting the challenges of neuro-Behçet differential diagnosis and a clinical case of a 34-year-old male patient with a criteria-based diagnosis of BD with neurological manifestations.

  • Open Access

    Quantitative and structural features of the SMN1 and SMN2 genes in patients with spinal muscular atrophy 5q

    by A. I. Vlasenko, V. D. Nazarov, S. V. Lapin, A. V. Mazing, E. A. Surkova, T. V. Blinova, T. M. Alekseeva

    Background. Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterized by loss of motor neurons. The cause of neurodegeneration is predominantly a homozygous deletion of the SMN1 gene, leading to a decrease in the synthesis of the SMN protein. The clinical picture of the disease is heterogeneous and varies depending on the age of onset and the ability to perform motor functions. Several genetic and molecular modifiers have been identified that are thought to influence the severity of SMA. One of the most proven factors is the number of copies of the SMN2 gene.Aim. Description of quantitative and structural features of the SMN1 and SMN2 genes in patients with SMA 5q.Materials and methods. The study included DNA samples from patients examined for the number of copies of the SMN1 and SMN2 genes at the Scientific and Methodological Center for Molecular Medicine, I.P. Pavlov First Saint Petersburg State Medical University, for the period from 2021 to 2022. Gene copy numbers were determined by multiplex ligation-dependent probe amplification using the SALSA MLPA P021 SMA kit (MRC Holland). We assessed an indirect parameter of aggressiveness (the age of the patient’s visit to the laboratory) to assess the severity of clinical manifestations of SMA. Statistical analysis was carried out using the statistical data processing program GraphPad Prism9.Results. A statistically significant direct correlation was found when studying the relationship between the number of copies of the SMN2 gene and the age of molecular diagnosis (r = 0.3960, p 0.0001). An assessment of the significance of differences between individual groups of patients gave a statistically significant result: 0.0001 when comparing groups of patients with 2 and 3 copies; 0.0001 – with 2 and 4 copies; 0.0370 – with 3 and 4 copies. 9 % of patients had a hybrid SMN1/SMN2 structure. Therefore, the significance of differences between the age of molecular diagnosis of patients with homozygous deletion of SMN1 and the age of molecular diagnosis of patients with the hybrid SMN1/SMN2 gene between groups with the same number of copies of the SMN2 gene was assessed. A statistically significant result (p = 0.0070) was found between patients with SMN1 deletion + 2 copies of SMN2 and patients with the hybrid gene SMN1/SMN2 + 2 copies of SMN2.Conclusion. The number of SMN2 gene copies correlates with the age of molecular diagnosis and indirectly predicts the age of SMA onset. The effect of the SMN1/SMN2 hybrid gene on the age of molecular diagnosis of SMA was comparable to the effect of the regular SMN2 gene.

  • Open Access

    Molecular mechanism of neurodegeneration in spinal muscular atrophy

    by A. I. Vlasenko, V. D. Nazarov, S. V. Lapin, A. V. Mazing, E. A. Surkova, T. V. Blinova, M. P. Topuzova, T. M. Alekseeva

    In the last decade, pathogenetic methods for the treatment of spinal muscular atrophy 5q have been developed. These include increased expression of the SMN2 gene, correction of SMN2 splicing, or reexpression of the SMN1 gene. Despite the comprehension of the genetic causes of the disease and the existence of therapies, it is still not completely known which molecular mechanisms in SMN protein deficiency lead to the degeneration of motor neurons. Understanding the molecular pathways involved in the loss of motor neurons may help develop new therapeutic strategies. The article presents genetic and biochemical data that reveal the molecular mechanisms of neurodegeneration in spinal muscular atrophy 5q.

  • Open Access

    Molecular markers of disease severity and response to nusinersen therapy in 5q spinal muscular atrophy (literature review)

    by K. D. Popov, T. M. Alekseeva, V. D. Nazarov, A. I. Vlasenko, S. M. Malyshev

    Currently, there are three drugs in the world for the pathogenetic therapy of spinal muscular atrophy 5q: nusinersen, risdiplam and onasemnogene abeparvovek. At the same time, it is still unknown to what extent this treatment is able to change the natural history of the disease, and the development of methods for evaluating the effectiveness of treatment is the subject of active scientific research. This article is a review of studies of laboratory approaches for assessing the disease severity and the response to nusinersen therapy in patients with spinal muscular atrophy 5q in various age groups.


  • Open Access

    Role of anti-inflammatory drugs in the complex therapy of patients with carpal tunnel syndrome

    by S. A. Zhivolupov, I. N. Samartsev, R. Z. Nazhmudinov, M. N. Vorobieva, A. I. Vlasenko

    Introduction. Carpal tunnel syndrome (CTS) is a neurological disease associated with tunnel mononeuropathies. There are various proven treatment regimens for patients with the use of conservative and surgical methods of treatment. Studies devoted to a comparative analysis of the effectiveness of methods of conservative therapy in patients with CTS are not enough to choose a treatment strategy.Purpose of the study. To study the therapeutic efficacy of wearing a wrist orthosis with and without the use of NSAIDs in the treatment of patients with CTS.Materials and methods. The study involved 40 patients (the average age of the participants was 32.8 ± 4.3 years) with a primary diagnosis of CTS, who were admitted to the neurological department of of the St Petersburg State Budgetary Healthcare Institution “Elizavetinskaya Hospital”, the Department of Medical Rehabilitation of St. Petersburg State Budgetary Healthcare Institution “St. Luke’s Clinical Hospital” in the period from 2017 to 2021. Patients were randomized into two comparable groups for complex conservative treatment and observation for 2 months of the dynamics of neurological symptoms, pain scale, QuickDASH questionnaire and neurophysiological parameters. The first group of patients received NSAIDs (Nimesil), 1 sachet (100 mg of nimesulide) twice a day after meals for 4 weeks, and the second group – NSAIDs with the imposition of a wrist orthosis for 4 weeks.Results. The study involved 40 patients. The average age of the participants was 32.8 ± 4.3 years (range from 20 to 48 years). Neurophysiological indicators in the studied groups at the screening stage were comparable: distal latency of the M-response (DLMO), ms; the amplitude of the negative peak of the M-response, mV; sensory latency (SL), ms and sensory impulse conduction velocity (SSPI), m / s: 5.7, 5.3, 3.5 and 31.8 in the first group and 5.4, 5.5, 3.8 and 32.4 in the second group (p > 0.05 when comparing the corresponding parameters). After the course of treatment, significant changes in the analyzed parameters were revealed (p < 0.05).Conclusions. In patients who received nimesulide and wore a wrist brace, the effectiveness of treatment was higher.